

Company Presentation October 3, 2018

Cantor Fitzgerald 2018 Global Healthcare Conference

Cautionary Note Regarding Forward-Looking Statements

Forward-looking statements

Some of the statements contained in this presentation are forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, in particular, statements about our plans, strategies, prospects and industry estimates. These statements identify prospective information and include words such as "anticipates," "intends," "plans," "seeks," "believes," "estimates," "should," "predicts," "hopes" and similar expressions.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Any forward-looking statements that we make in this presentation speak only as of the date of such statement, and we undertake no obligation to update such statements.

Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. The matters referred to in the forward-looking statements contained in this presentation may not in fact occur.

We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions.


Please refer to the cautionary statements and risk factors contained in our filings with the Securities and Exchange Commission (the "SEC"), including in our Form 10-K filed on February 26, 2018 and our Form 10-Q filed on August 1, 2018, as well as other documents that may be filed by the Company from time to time with the SEC. Copies may be obtained at <u>www.sec.gov</u> and on our website at <u>www.Lantheus.com</u>. Except to the extent required by law, we do not undertake any obligation to update any forward-looking statements, and we caution you against relying on any forward-looking statements.

Non-GAAP measures

This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Company's business and its performance. These measures are not calculated in accordance with U.S. GAAP and should not be considered in isolation, or as a substitute for the most directly comparable GAAP financial measure. Our computations of these non-GAAP measures may differ from those of other companies. A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures can be found in our Current Reports on Form 8-K furnished to the Securities and Exchange Commission, the most recent of which was filed on August 1, 2018. Copies may be obtained at www.sec.gov and on our website at www.lantheus.com.



60+ Years of Innovation, Providing Leading/Best-in-Class Imaging Agents and Products



Lantheus at-a-Glance

- Diversified portfolio serving Echocardiography and Nuclear Medicine specialties
 - > Products focused on diagnostic accuracy and patient management
 - > Lead products include:
 - DEFINITY®: ~80% Market Share
 - TechneLite®: ~40% Market Share
 - Xenon: ~90% Market Share
 - > Dynamic pipeline contains promising next-generation imaging agents
- Worldwide distribution partnerships covering EU, APAC and LatAm regions
- Operations in U.S., Puerto Rico and Canada with headquarters in North Billerica, MA
- ~500 employees including the largest dedicated Echocardiography sales force based in North America
- IPO in June 2015 (Ticker: LNTH)
- Market cap of ~\$606MM (source: Bloomberg 31-AUG-2018)



Schematic for illustrative purposes only. Please see Indications and full Prescribing Information on product specific pages at www.Lantheus.com.

Enhance the growth trajectory and profitability of our core microbubble franchise

Augment and invest in our pipeline with focus on emerging technologies

Pursue complementary, external opportunities that fit with our objective to deliver long-term sustainable growth and profitability



Imaging Agents Well-Positioned to Take Advantage of Macro Trends


Imaging Agents Help Physicians...

- Detect disease earlier
- Make differentiated treatment decisions
- Provide more tailored treatment
- Reduce the need for additional testing and invasive procedures
- Reduce cost burden to healthcare system


...And Benefit Patients Through

- Improved timeliness and precision of diagnoses
- Better informed care plans
- Reduced likelihood of unnecessary downstream procedures
- Potential lower radiation exposure compared to other modalities
- Potential for decreased out-of-pocket costs

Global Radiopharmaceuticals Market



Global Medical Imaging Market





Diversified Portfolio Serving Echocardiography and Nuclear Medicine

Lantheus Medical Imaging

Specialties & Products

Echocardiography

 One of the most widely used diagnostic tests in cardiology; facilitates diagnosis early in the continuum of care

 $^{\sim}33MM$ echocardiography (echo) studies performed annually in the US*

~20% of echo studies are deemed suboptimal and could benefit from the use of a contrast agent used to improve image quality**

Echo contrast agents are sold directly to hospitals, clinics and group practices in the US



Nuclear Medicine

- Radioactive pharmaceuticals (radiopharmaceuticals) are used in 100% of nuclear imaging studies
- Radiopharmaceutical products require complex supply chain capabilities and just-in-time shipments
- Lantheus' products are primarily distributed to ~300 radiopharmacies through four commercial radiopharmacy groups (Cardinal, UPPI, GE Healthcare and Triad Isotopes), responsible for ~97% of the aggregate SPECT*** doses sold in US





*Data on File, Lantheus Medical Imaging, Inc.

**Mulvagh S et al. J Am Soc Echocardiogr. 2008;21(11):1179-1201; Waggoner AD, et al. J Am Soc Echocardiogr. 2001;14(5):417-420.; Bulwer BE, Solomon SD, ed. Essential

Echocardiography, a Practical Handbook with DVD. Totowa, NJ: Humana Press; 2007:89-118. ***Sinale Photon Emission Computed Tomography


Serial Pioneers in the Field of Radiopharmaceuticals

Leader Today

 History of launching many first-in-class radiopharmaceutical products to aid clinicians in diagnosing, staging and prognosis of disease — advanced market from planar to SPECT imaging

Leader Tomorrow

- Focused on emerging technologies to fulfill unmet diagnostic medical imaging needs moving market from SPECT to PET imaging
- PET offers many advantages to SPECT, including:
 - Improvements in image quality and diagnostic accuracy
 - > Ability to quantify tissue perfusion and gather additional physiological information
- Potential to improve diagnostic accuracy and patient management





Development Pipeline Focused on Emerging Technologies

			Development Phase				
Candidate	Imaging Modality	Imaging Application	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Flurpiridaz F 18	PET	Myocardial Perfusion					
LMI 1195	PET	Heart Failure / Sudden Death					
Vascular Remodeling Imaging Agent (LMI 1174)	MRI	Atherosclerosis / Vulnerable Plaque					

Flurpiridaz F 18: Next-generation PET MPI agent; particularly promising in difficult-to-image patient types, including obese and female patients

- > In April 2017, Lantheus entered into a definitive license agreement with GE Healthcare for the worldwide development and commercialization of the agent; second Phase 3 trial started in June 2018
- LMI 1195 is an internally discovered small molecule that we believe may be a first-in-class fluorine-18-based PET imaging agent designed to assess cardiac sympathetic nerve function; we believe it could become a useful tool in the diagnostic assessment of ischemic heart failure patients at risk of sudden cardiac death
 - Collaborations with academic centers in the U.S., Canada and Europe yielded clinical data in ischemic heart failure patients deemed adequate by the FDA to support advancing to a single Phase 3 clinical trial to support our NDA submission; Lantheus is currently in special protocol assessment review process with the FDA for a Phase 3 trial

LMI 1174 is a vascular remodeling imaging agent to identify vulnerable plaque located in the cardiovascular system

> Lantheus is working closely with investigators in the U.S. and Europe to develop additional preclinical data to enter into initial clinical trials



Pursuit of External Opportunities

Pursuing complementary, external opportunities across the broader Life Sciences sector that fit with our objective to deliver long-term sustainable growth and profitability

- Evaluating the broader imaging landscape and therapeutic adjacencies as key areas for potential expansion through M&A and in-licensing
- Focus on assets that are or can soon be accretive to revenue and create the ability to improve our profit margins and cash flow
- Open to a broad range of deal sizes and structures, with an eye toward strategic fit and assets that are already commercial or close to commercialization that will then be accretive to earnings within a short time horizon
- Capitalize on our collective expertise and create positive synergies that will help to ensure our commercial success



Key Company Highlights

3-Pronged Corporate Growth Strategy

Essential, Growing Markets Market Leading Platform of Products Competitive Channel Advantages, Supply Chain Expertise Continued Growth, Optimization of Capital Structure





Appendix

Management Team







Mike Duffy Senior Vice President – Law and Public Policy, General Counsel and Secretary



ROPES&GRAY







Robert Marshall Chief Financial Officer and Treasurer

ZIMMER BIOMET Your progress. Our promise:



Sarah Le Roy Senior Vice President – Human Resources

FikeGoldmanLinkage



Simon Robinson Senior Vice President – Research & Pharmaceutical Development





John Bolla Senior Vice President – Technical Operations

SSK GlaxoSmithKline



Etienne Montagut Senior Vice President – Corporate Development







Carol Walker Senior Vice President – Quality





Disciplined Financial Management Built Upon a Foundation of Performance

Opportunistic approach to scale, diversification and de-risking of business through strategic initiatives

- Target acquisitions and strategic licenses leveraging core competencies; focus on balance sheet optimization
- Prudent financial management remains a central tenet of strategic and operating policies

Thoughtful approach to leverage

- From June 2015 to June 2018, approximately \$136.4MM of debt repayment
 - ✓ Pre-payable debt and positive free cash flow support approach
 - ✓ Total Gross Leverage of 3.0x as of 30-JUN-2018**

Ample sources of liquidity supporting operations and opportunities


- ✓ \$75MM available under revolving credit facility
- ✓ Cash on balance sheet (\$86.5MM at 30-JUN-2018)

Strong operational performance and margin improvement

- \checkmark Contracting strategy supports predictable revenue and production levels
- Resourceful approach to supply chain logistics coupled with agile operational infrastructure enables opportunistic sales
 - ✓ Focused on addressing business footprint and capital structure efficiencies
 - Improved profitability leading to robust free cash flow of ~\$88MM in the last three full fiscal years*



Strong Performance Over Prior Year





* Includes the impact of a \$5.0 million up-front payment from GE Healthcare under the flurpiridaz F 18 collaboration and license agreement;

without the GE payment, FY-17 revenue totaled \$326.4 million, FY-17 Adjusted EBITDA totaled \$89.1 million

**Adjusted EBITDA to Net Income reconciliation available in earnings press releases at <u>www.Lantheus.com</u> 13

Quarterly Financial Results

(\$ in millions)


Commentary

Revenues

Delivered \$85.6 million in worldwide revenue for second quarter 2018, driven by robust DEFINITY sales

- DEFINITY continued strong performance with worldwide revenues totaling \$46.1 million, an increase of 14.9% over second quarter 2017
- TechneLite revenue of \$23.5 million, a decrease of 12.1% compared to second quarter 2017, primarily a result of a Mo-99 supply interruption experienced with one supplier
- Xenon revenue for the second quarter 2018 was \$7.6 million, essentially flat when compared with \$7.9 million in the second quarter of 2017

"Other" product category was \$8.4 million in second quarter 2018, compared to \$14.1 million one year ago, which included a \$5.0 million up-front payment from GE Healthcare under the flurpiridaz F 18 collaboration and license agreement



DEFINITY Revenues



s s




Quarterly Financial Results

(\$ in millions)


Commentary

Gross profit improvement reflects the increased contribution of DEFINITY to total revenue mix

Second quarter 2018 Adjusted EBITDA results driven by a combination of strong cost management and timing of certain R&D expenses that will be incurred during the remainder of 2018









Historical Annual Operating Performance


(\$ in millions)


Commentary

- Maintained ~80% market-share in DEFINITY, protecting price while driving additional market penetration
- Nuclear Medicine contracting strategy drives agreements with Cardinal, UPPI, GE Healthcare and Triad specifying pricing levels and requirements to purchase minimum shares of certain products during certain periods

DEFINITY Revenues

Optimizing portfolio mix by driving higher-margin products and operational improvements, as well as lower interest expense










Historical Credit Metrics

Commentary


- From June 2015 through December 31, 2017, approximately \$135MM of debt repayment through proceeds from IPO, two follow-on equity offerings and cash on hand
- Profitability driven by portfolio mix-shift to higher margin products as well as various efficiency programs
- Efficiency programs include the completion of Canadian and Australian radiopharmacy divestures, subsequent supply agreements with purchasers and Xenon process tech transfer

Ratio of Total Debt and Net Debt to Adjusted EBITDA



■ Total leverage ■ Net leverage

Free Cash Flow Conversion





Capitalization

As of 30-JUN-2018 (in \$MM)

	Amount
Cash & Cash Equivalents	\$86.5
\$75.0MM Revolving Credit Facility due 2022	-
\$275.0MM Term Loan Facility due 2022	\$271.6
Total Debt	\$271.6
Market Value of Equity ¹	\$557.2
Total Capitalization	\$828.8
06/30/18 Adj. EBITDA (LTM)	\$90.2
Total Gross Leverage	3.0



¹ Based on stock price of \$14.55 as of 30-JUN-2018

Adjusted EBITDA Reconciliation


(\$ in thousands)

	Three Months Er	Three Months Ended, June 30		
	2018	2017*		
Net income	9,745	13,595		
Interest expense, net	4,290	4,280		
Income tax expense	1,531	78		
Depreciation	1,854	3,450		
Amortization of intangible assets	1,639	1,661		
EBITDA	19,059	23,064		
Stock and incentive plan compensation	2,399	1,510		
Asset write-off	774	961		
Severance and recruiting costs	242	228		
Offering and other costs	_	351		
Campus consolidation costs	587	666		
Debt refinancing costs	_	26		
Extinguishment of debt and debt retirement costs	_	_		
New manufacturer costs	599	1,141		
Adjusted EBITDA	23,660	27.947*		



Financial Results

(\$ in millions)



*Includes the impact of a \$5.0 million up-front payment from GE Healthcare under the flurpiridaz F 18 collaboration and license agreement

31.5%

\$27.9

45.9

------% Gross Profit Margin

27.8%

\$22.7

48.9%

39.8

28.3%

\$22.6



27.6%

\$23.

51.2%

27.9%

\$23

51.2%

Q4-17 Q1-18 Q2-18

25.7%

\$20.8


Product Segment Overview

% of FY 2017 sales 47% 32% 12% 9% TechneLite Xenon DEFINITY Other **Primary Indication: Cardiac Primary Indication: Numerous** Primary Indication: Pulmonary U.S. International U.S. International U.S. International U.S. International \$76 \$157 \$132 \$60 \$112 \$42 \$105 \$49 \$94 \$96 \$29 \$73 \$99 \$38 Reve \$37 \$31 45 90 94 82 85 **24** 15 28 37 49 62 15 ř '15 '16 '14 '15 '16 '17 '14 '15 '16 '17 '14 15 16 17 '14 '17 Leading ultrasound injectable contrast Self-contained system, or generator, Xenon Xe 133 Gas ("Xenon") is a Technetium labeled imaging agents . imaging agent used by cardiologists of technetium (Tc99m), a radioisotope radiopharmaceutical gas that is used with SPECT, a fluorine-18and sonographers during with a six hour half-life, used by inhaled and used to assess pulmonary radiolabeled agent used with PET, echocardiography exams radiopharmacies to prepare various function and also cerebral blood flow cyclotron-produced agents, and our nuclear imaging agents only therapeutic product ð ~80% market share in the U.S. ~90% market share in the U.S. ~40% market share in the U.S. For Molybdenum-99: Institute for Radioelements (Belgium) JHS ANSTO (Australia) Institute for Radioelements . (Belgium) NTP radioisotopes (South Africa) . There are 2 other echocardiography Dynamics in the generics market have Three other approved products in the In March 2016, Curium (MNK's contrast agents approved by the FDA: US: Curium, GE Healthcare, NorthStar Nuclear Imaging business) received made it possible for more competitors FDA approval and re-launched their to enter the market Optison from GE Healthcare Xenon product Lumason from Bracco Diagnostics




DEFINITY Improves Quality and Diagnostic Outcomes Across Clinical Settings

In a Study of Technically Difficult to Interpret Echoes, DEFINITY Significantly Increased the Percentage of Adequate Studies




Unenhanced



MICU=medical intensive care unit; SICU=surgical ICU. *P<.0001 comparing quality before and after contrast for total and all subgroups. Kurt M et al. J Am Coll Cardiol. 2009;53(9):802-810.



DEFINITY: Echo Contrast Agent of Choice



Microbubble Franchise

Multi-faceted approach, including pursuing Left Ventricular Ejection Fraction (LVEF) indication,

new patent protection, new formulations, additional product offerings, and specialized manufacturing capabilities





Nuclear Medicine Agents: Delivering Essential Products Daily

> First in providing low-enriched uranium (LEU) generators

> One of four approved products in the US

Leading provider of Xenon in the US

processed and finished by Lantheus

TechneLite: Technetium (Tc99m) generator used to prepare patient-specific radiolabeled imaging agents such as Neurolite and Cardiolite; technetium results from radioactive decay of molybendum-99 (Mo-99) produced in

Xenon-133 Gas: Inhaled radiopharmaceutical imaging agent used to assess pulmonary function and image

Xenon is manufactured by the Institute for Radioelements (IRE) as a bi-product of Mo-99 production and is

Stable market

cerebral blood flow

nuclear research reactors

















Additional Products: 6 other injectable radiopharmaceutical products

*Positron Emission Tomography

Unique Corporate Capabilities Create Competitive Advantage

Quality

- Strong execution and quality control culture supports just-in-time manufacturing model
- Expertise in design, development and validation of complex manufacturing systems and processes
- All products flow through Lantheus for quality control testing

Efficiency

- Timely receipt of radioactive raw materials from global locations most balanced and diversified Mo-99 supply chain in the industry
- Automated TechneLite production line
- Coordination of specialized freight and transport companies to geographically disparate molecular imaging providers

Compliance

- Experienced in handling of nuclear materials
- Numerous federal government and regulatory agencies (FDA, EMA, NRC, EPA, DOT, DHS, DOE)
- Multiple state and provincial health departments and boards of pharmacy

Customer Service

- Deep, long-standing customer relationships
- Time-sensitive order management, customer verification, packaging, and distribution for just-in-time shipments to address short half-life
- Significant global logistics expertise across product portfolio









TechneLite[®] generators

Lantheus

Lantheus production of TechneLite: from the reactor to the patient in 2-5 days





Company Presentation October 3, 2018

Cantor Fitzgerald 2018 Global Healthcare Conference